bioAffinity Technologies, Inc. (BIAF) · Oct 8, 2026 · Other events

bioAffinity patent allowance expands CyPath Lung’s Asian moat

Japan patent allowance — Notice of Allowance; issuance follows payment of the applicable fee

bioAffinity’s new Japan patent allowance strengthens CyPath Lung’s IP protection, but it does not yet add revenue, clearance, or commercial access.

bioAffinity is in the early commercialization phase for CyPath Lung, with physician adoption accelerating but the company still building scale around a single commercial diagnostic. CyPath Lung test volume rose 216% year over year in Q2 2026, while first-half testing revenue increased 156%, according to the company’s latest reported results.

The filing adds useful Asian intellectual-property protection, but not a new commercial milestone. The Japan Patent Office issued a Notice of Allowance for the AI-driven method behind CyPath Lung, which would become the company’s first CyPath Lung patent awarded in Japan and its fifth in Asia, including China and Hong Kong. 〔0〕

The protection is meaningful because it supports the company’s expansion story, but the legal step is not complete yet. This is an allowance indicating an intention to grant a patent, not the final issued patent; issuance is expected only after payment of the applicable fee. 〔1〕 The filing therefore strengthens bioAffinity’s ability to protect its technology in Japan, but it does not establish Japanese sales, regulatory clearance, reimbursement, licensing revenue, or physician adoption.

The event is incremental rather than transformative for the business. bioAffinity already had a broad portfolio—22 awarded U.S. and foreign patents and 36 pending applications—so Japan adds geographic depth to an existing protection strategy rather than changing CyPath Lung’s development or commercialization status.

The underlying product remains commercially available but still requires clinical adoption to convert its claimed performance into growth. CyPath Lung is marketed as a laboratory-developed test, is not intended to be used as a sole diagnostic tool, and must be considered alongside other clinical findings. 〔2〕 That makes the patent strategically helpful, but secondary to the more important proof points: continued test volume growth, broader physician use, and eventual expansion beyond the current U.S.-centered commercial base.

Bottom line: The Japan allowance modestly advances bioAffinity’s long-term Asian commercialization story by protecting CyPath Lung’s technology. It matters as an IP-building step, but it does not yet change near-term revenue or market access.

What to watch next

Japanese patent issuance after applicable fee payment

Original filing on SEC EDGAR

More bioAffinity Technologies, Inc. news

bioAffinity patent allowance expands CyPath Lung’s Asian moat | BIAF Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.